Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma
Second approval in China in three weeks following the R/R MM indication announced on January 13, 2025
Paris, January 31, 2025. The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT) based on data from the IMROZ phase 3 study.
Global Head, Oncology'When Sanofi entered China more than four decades ago, we did so with the intention of bringing potentially transformative therapies to Chinese patients. This approval, occurring just weeks after Sarclisa's first in the country, represents tremendous progress towards advancing this mission. Now, patients with multiple myeloma and their providers have access to two new Sarclisa-based regimens that have the potential to improve outcomes across lines of therapy.'
This approval closely follows the decision from the NMPA earlier in January 2025, approving Sarclisa in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Beyond China, in the Asia-Pacific region, a regulatory submission for Sarclisa in NDMM patients not eligible for hematopoietic stem cell transplantation (HSCT) is currently under review in Japan.
About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US Food and Drug Administration.
Currently, Sarclisa is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple indications. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study.
Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous (SC) administration method for Sarclisa in clinical studies. In January 2024, Sanofi reported positive results from the IRAKLIA phase 3 study evaluating Sarclisa SC formulation administered via an on-body delivery system (OBDS) in combination with Pd compared to intravenous (IV) Sarclisa in patients with R/R MM. In December 2024, additional positive results from the program, including the GMMG-HD7 phase 3 study evaluating Sarclisa-RVd induction therapy in transplant-eligible NDMM patients, were also presented at the 66th American Society of Hematology Annual Meeting and Exposition. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery.
In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centered on difficult-to-treat often rare cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well as gastroenteropancreatic neuroendocrine tumors and other gastrointestinal and lung cancers.
For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov.
About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com Nicolas Obrist | +33 6 77 21 27 55 | nicolas.obrist@sanofi.com Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.comFelix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com Keita Browne | +1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
All trademarks mentioned in this press release are the property of the Sanofi group.Attachment
Press Release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Insane amount Aussies could pay for coffee
Coffee may need to reach $12 a cup for Australia to compete with other countries for the sacred beans. Benchmark prices hit an all-time high in April, and industry insiders say Chinese demand for beans is squeezing prices in Australia. '(The) Chinese have very much converted from tea to coffee,' Essential Coffee chief executive Todd Hiscock told the ABC. 'They're buying up unprecedented levels of coffee supplies, often they're taking a whole Brazilian stock load in ways that's never been seen before.' Median prices per cup needed to increase to between $8 to $12, he said. 'We've got to come to the party and pay in a competitive global market,' Hiscock said. Brazil produces more than one-third of the world's coffee beans. The country battled through a drought in 2024 that was capped off with a cold snap. Combined, this slashed the overall harvests. As investors turn away from the volatile US, the Brazilian real has also climbed, disincentivising exports out of Brazil. Vietnam is the second-largest coffee producer. The El Nino weather pattern plunged Vietnam's coffee-growing regions into drought for the past two years, damaging the plants so badly that many will not fully recover for another two years. These international pressures, plus general inflation, are slicing margins at Australian cafes. A large player in the Australian coffee industry, Essential Coffee's wage bill has risen 9 per cent in two years, combined with a 29 per cent increase in rent and a 6 per cent rise in insurance. Mr Hiscock told the ABC the price of wholesale coffee had risen 119 per cent since November 2023. 'It's hard because people are very sensitive to their beloved coffee and when you move the price up, you find not just a lot of negative reaction, you find some very terse expletives,' he said.
Yahoo
2 hours ago
- Yahoo
Asian Growth Companies With High Insider Ownership And Up To 38% Earnings Growth
As the Asian markets navigate a landscape of economic uncertainties and evolving trade dynamics, investors are increasingly turning their attention to companies with strong growth potential and significant insider ownership. In this environment, stocks that combine robust earnings growth with high levels of insider investment can offer unique insights into company confidence and strategic alignment. Name Insider Ownership Earnings Growth Techwing (KOSDAQ:A089030) 18.8% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 26.9% Shanghai Huace Navigation Technology (SZSE:300627) 24.4% 23.5% Schooinc (TSE:264A) 30.6% 68.9% Samyang Foods (KOSE:A003230) 11.7% 24.3% Oscotec (KOSDAQ:A039200) 21.1% 94.4% Nanya New Material TechnologyLtd (SHSE:688519) 11% 63.3% Laopu Gold (SEHK:6181) 35.5% 40.2% Fulin Precision (SZSE:300432) 13.6% 44.2% Click here to see the full list of 614 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ingenic Semiconductor Co., Ltd. focuses on the research, development, design, and sale of integrated circuit chip products both in China and internationally, with a market cap of CN¥31.92 billion. Operations: Ingenic Semiconductor Co., Ltd. generates revenue through the research, development, design, and sale of integrated circuit chip products in both domestic and international markets. Insider Ownership: 16.6% Earnings Growth Forecast: 26.1% p.a. Ingenic Semiconductor Ltd. demonstrates potential as a growth company with high insider ownership in Asia, despite recent challenges. The company's revenue is forecast to grow at 18.2% annually, outpacing the broader Chinese market's 12.4%, and its earnings are expected to rise significantly by 26.1% per year, surpassing market averages. However, recent amendments to company bylaws and dividend decreases may indicate internal restructuring efforts amidst declining net income from CNY 537.25 million in 2024 to CNY 366.2 million in the latest report. Delve into the full analysis future growth report here for a deeper understanding of Ingenic SemiconductorLtd. The analysis detailed in our Ingenic SemiconductorLtd valuation report hints at an inflated share price compared to its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: Allwinner Technology Co., Ltd. is engaged in the research, development, design, manufacturing, and sale of intelligent application SoC, analog components, and wireless interconnect chips in China with a market cap of CN¥32.09 billion. Operations: The company's revenue is primarily derived from its Integrated Circuit Design segment, which generated CN¥2.50 billion. Insider Ownership: 37.4% Earnings Growth Forecast: 38.1% p.a. Allwinner Technology Ltd. exhibits strong growth prospects with earnings expected to increase by 38.1% annually, surpassing the Chinese market's average growth rate. The company's recent financial performance reflects this potential, as Q1 2025 sales rose to CNY 619.86 million from CNY 409.51 million the previous year, while net income increased to CNY 91.55 million from CNY 49.09 million. Despite high-quality earnings being impacted by large one-off items, revenue is forecasted to grow at a robust rate of over 20% annually. Click here and access our complete growth analysis report to understand the dynamics of Allwinner TechnologyLtd. Upon reviewing our latest valuation report, Allwinner TechnologyLtd's share price might be too optimistic. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Round One Corporation operates indoor leisure complex facilities and has a market cap of ¥340.32 billion. Operations: The company's revenue segments include ¥102.49 billion from Japan and ¥73.11 billion from the United States of America. Insider Ownership: 36.2% Earnings Growth Forecast: 12.8% p.a. Round One Corporation demonstrates solid growth potential with earnings projected to grow 12.8% annually, outpacing the Japanese market average. The company benefits from high insider ownership and trades at a good value relative to peers. Despite recent share price volatility, Round One's sales in Japan and the USA have shown healthy increases, boosting confidence in its revenue trajectory. Additionally, recent buybacks indicate management's commitment to enhancing shareholder value amidst stable dividend payouts. Take a closer look at Round One's potential here in our earnings growth report. The valuation report we've compiled suggests that Round One's current price could be quite moderate. Access the full spectrum of 614 Fast Growing Asian Companies With High Insider Ownership by clicking on this link. Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SZSE:300223 SZSE:300458 and TSE:4680. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Undervalued Asian Small Caps With Insider Buying To Consider
In recent weeks, the Asian markets have experienced a mix of challenges and opportunities, with Chinese stocks gaining traction amid hopes for government stimulus and Japan's economy showing signs of moderate recovery despite some economic headwinds. In this context, identifying promising small-cap stocks involves looking at companies that can navigate these dynamic conditions effectively, often indicated by insider buying as a potential sign of confidence in their future performance. Name PE PS Discount to Fair Value Value Rating Security Bank 4.4x 1.0x 36.78% ★★★★★★ East West Banking 3.1x 0.7x 33.66% ★★★★★☆ Lion Rock Group 5.0x 0.4x 49.52% ★★★★☆☆ Dicker Data 18.6x 0.6x -14.39% ★★★★☆☆ Atturra 28.1x 1.2x 33.01% ★★★★☆☆ Sing Investments & Finance 7.4x 3.7x 38.56% ★★★★☆☆ AInnovation Technology Group NA 2.3x 48.90% ★★★★☆☆ Integral Diagnostics 152.5x 1.8x 35.74% ★★★☆☆☆ China Lesso Group Holdings 7.0x 0.4x -385.29% ★★★☆☆☆ Tabcorp Holdings NA 0.6x -26.36% ★★★☆☆☆ Click here to see the full list of 62 stocks from our Undervalued Asian Small Caps With Insider Buying screener. Here's a peek at a few of the choices from the screener. Simply Wall St Value Rating: ★★★★☆☆ Overview: Bloomberry Resorts operates integrated resort facilities, primarily focusing on gaming and entertainment, with a market capitalization of ₱116.89 billion. Operations: The company's primary revenue stream is from its integrated resort facility, with recent quarterly revenue reaching ₱54.66 billion. It has experienced fluctuations in net income margins, with a notable high of 21.96% and a low of -75.72%. The gross profit margin has shown variability as well, peaking at 95.27% and dropping to 27.53%, reflecting changes in cost management efficiency over time. Operating expenses have been significant, impacting profitability alongside non-operating expenses such as depreciation and amortization costs. PE: 17.4x Bloomberry Resorts, a notable player in the Asian hospitality sector, recently showcased strong financial performance with first-quarter sales of PHP 12.93 billion and net income rising to PHP 3.32 billion. Insider confidence is evident as Cyrus Sherafat acquired over 9 million shares for approximately PHP 69.93 million between March and May 2025. Despite volatility in its share price, the company maintains a promising growth outlook with earnings projected to grow annually by over 11%. Delve into the full analysis valuation report here for a deeper understanding of Bloomberry Resorts. Assess Bloomberry Resorts' past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★☆☆☆ Overview: China Lesso Group Holdings is a leading industrial group in China specializing in the production and sale of building materials and interior decoration products, with a market cap of approximately CN¥22.48 billion. Operations: The company generates revenue primarily from its Plastics & Rubber segment, with a reported revenue of CN¥27.03 billion. The cost of goods sold (COGS) for the same period was CN¥19.73 billion, leading to a gross profit margin of 26.99%. Operating expenses, including sales and marketing as well as general and administrative costs, totaled CN¥3.42 billion, while non-operating expenses amounted to CN¥2.19 billion. The net income for the period was CN¥1.68 billion, resulting in a net income margin of 6.23%. PE: 7.0x China Lesso Group Holdings, operating in the construction materials sector, exhibits potential value with a forecasted earnings growth of 12.29% annually. Despite a drop in sales to CNY 27 billion and net income to CNY 1.68 billion for 2024, insider confidence is evident through recent share purchases by executives throughout early 2025. The company approved a HK$0.20 per share dividend for shareholders, indicating financial stability despite external borrowing risks. Leadership changes include appointing Mr. Huang Zhanxiong as an executive director, focusing on strategic expansion into new energy storage markets, which could drive future growth opportunities. Click here to discover the nuances of China Lesso Group Holdings with our detailed analytical valuation report. Evaluate China Lesso Group Holdings' historical performance by accessing our past performance report. Simply Wall St Value Rating: ★★★★★☆ Overview: Shougang Fushan Resources Group is engaged in the coking coal mining industry, with operations focused on producing and selling coking coal. Operations: The primary revenue stream comes from coking coal mining, with recent revenues reaching HK$5.06 billion. The gross profit margin has shown variability, peaking at 68.34% and recently recorded at 51.18%. Operating expenses are primarily driven by general and administrative costs, along with sales and marketing expenses. PE: 9.1x Shougang Fushan Resources Group, a small player in Asia's market, recently saw insider confidence with Deputy MD & Executive Director Zhaoqiang Chen purchasing 640,000 shares valued at HK$1.52 million in March 2025. Despite earnings forecasts predicting a 1.9% annual decline over the next three years and reliance on higher-risk external borrowing for funding, the company proposed a dividend increase to HK$0.21 per share for 2024. Recent board changes include Xu Qian's appointment as non-executive director, bringing extensive financial expertise to the table amidst an auditor rotation aimed at enhancing corporate governance. Get an in-depth perspective on Shougang Fushan Resources Group's performance by reading our valuation report here. Gain insights into Shougang Fushan Resources Group's historical performance by reviewing our past performance report. Dive into all 62 of the Undervalued Asian Small Caps With Insider Buying we have identified here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PSE:BLOOM SEHK:2128 and SEHK:639. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
